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Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia
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ABSTRACT
Background
There are limited treatment options for older patients with acute myeloid leukemia and prognosis remains poor, thereby warranting development of novel therapies. We evaluated the efficacy and safety of azacitidine in combination with lenalidomide as front-line therapy for older acute myeloid leukemia patients.
Design and methods
Patients >60 years of age with untreated acute myeloid leukemia received azacitidine 75mg/m 2 for 7 days followed by escalating doses of lenalidomide daily for 21 days starting on day 8 of each cycle every 6 cycles. Patients received continued therapy until disease progression, unacceptable toxicity, or completion of 12 cycles.
Results
Forty-two patients (median age, 74 years) were enrolled with equal distribution according to ELN risk. Overall response rate was 40% (CR+CRi rate = 28%). The median time to CR/CRi was 12 weeks, and duration of CR/CRi was 28 weeks (range, 4->104 weeks). Therapy-related acute myeloid leukemia and high hematopoietic cell transplantation comorbidity index were negative predictors of response. Early death was noted in 17% of patients. Grades ≥ 3 toxicities were uncommon and most adverse events were gastrointestinal, fatigue and myelosupression.
INTRODUCTION
Two-thirds of patients with acute myeloid leukemia (AML) are over 60 at diagnosis. Since the introduction of anthracyclines combined with cytarabine as front-line therapy 1 outcomes for these patients have remained poor. Adverse biological features, which are more common in older patients, coupled with decreased tolerance to conventional chemotherapy, are the main causative factors for these poor outcomes. 2 Alternative treatment approaches for elderly patients with AML are needed.
Pathological epigenetic modifications, including aberrant DNA methylation, likely contribute to the pathogenesis of AML. 3 Aberrant DNA methylation can be pharmacologically reversed by inhibitors of DNA methyltransferase (DNMT) enzymes, and a retrospective analysis suggests that AML patients with low blast counts derive a survival benefit following treatment with the DNMT inhibitor 5-azacitidine (aza) compared to conventional care. 4 Lenalidomide, an immunomodulatory agent with a distinct and non-overlapping mechanism of action, 5 possesses clinical activity against several myeloid malignancies including AML.
Furthermore, pre-clinical data suggests that lenalidomide has, at least, additive activity when combined with cytosine analogues against AML cells, 6 thus we aimed to determine the efficacy and safety profile of the sequential combination of aza followed by lenalidomide in elderly patients with untreated AML.
DESIGN AND METHODS
Patient population
From 
Study design
As previously shown, the first 16 patients were enrolled on the dose finding portion of the study following a typical '3+3' dose escalation schema. All patients received azacitidine 75 mg/m 2 /day intravenously or subcutaneously for 7 days followed by escalating doses (5mg, 10mg, 25mg and 50mg) of lenalidomide orally for 21 days starting on day 8 of each cycle. This was followed by 14 days of observation, for a total 42-day cycle. 8 Treatment cycles were individually customized based on response and toxicity as follows: (1) subjects with evidence of persistent AML (≥5% blasts) received repeated cycles of the combination. None of these patients had dose reductions; (2) subjects with no morphologic evidence of AML (<5% blasts), received repeated cycles of the combination. For those subjects without evidence of AML but who had grade 4 neutropenia (<500/µL) of at least 14-day duration lenalidomide dose was reduced to previous dosing level for the subsequent cycles. A second 7 dose reduction was permitted if the neutropenia occurred again following initial dose reduction.
One Azacitidine dose reduction was permitted if the cytopenia persisted following initial two lenalidomide dose reductions. Similarly, for subjects without evidence of AML but who had grade 3-4 non-hematological malignancies, lenalidomide dose was reduced to previous dosing level for the subsequent cycles. Hematologic toxicity was not evaluable in patients with baseline neutropenia (<500/mm 3 ) or thrombocytopenia (<20,000/mm 3 ); these patients were administered 42-day treatment cycles with supportive care measures as needed. For patients with an absolute neutrophil count >500/mm 3 , a non-transfused platelet count of >20,000/mm 3 at baseline or those with peripheral blood count recovery after response to therapy, dose reductions were recommended after peripheral blood count recovery before initiating the next cycle. Growth factors were allowed, but not recommended, for subjects without evidence of AML with neutropenia.
Study assessments and statistical analysis
Responses were assessed according to the European LeukemiaNet (ELN) guidelines. 10 Patients who received at least one dose of azacitidine were considered evaluable. In the Phase II portion of the study we enrolled 31 patients on a 2-stage design. Using a null hypothesis of a 20% OR rate and an alternative hypothesis of a 43% OR rate, with a significance of 5.3%, an interim analysis was performed after eight patients are evaluable. Given that 5 responses had been noted, the trial was not stopped for futility and 22 more patients were accrued to a total of 30 patients. This design allowed an 84% power to reject the null hypothesis if the alternative hypothesis was correct, making the probability of stopping early 50% if the null hypothesis was correct and 8% if the alternative hypothesis was correct. Cytogenetic and molecular risk 8 stratification also followed the ELN classification. 11 Duration of response was measured only in responding patients as the length of time after achievement of a response (CR, CRi or PR) during which a patient survived without evidence of disease progression. Survival was measured from the first day of azacitidine treatment to death from any cause. Kaplan-Meier analysis was used to estimate response duration and overall survival. The impact of clinical characteristics on outcomes was assessed by a Wilcoxon test for continuous data or a Fisher's exact test for categorical variables and was not adjusted for multiple comparisons. Log-rank tests were used to assess differences between survival curves. All tests were two-sided, with a significance level of 0.05. Confidence intervals (CI) were established at 95%.
Processing of biological samples and Genomic Profiling
Bone marrow aspirate was collected in heparin or ethylenediaminetetraacetic acid tubes. The samples were diluted 4x with PBS before the addition of Ficoll-Hypaque (Sigma-Aldrich, St
Louis, MO, USA) density gradient. After centrifugation, the plasma and mononuclear layers were collected and stored at -80 o C.
Screening for mutations in FMS-like tyrosine kinase 3 internal tandem duplication (FLT-3-ITD) and D835 tyrosine kinase domain (FLT-3-TKD), nucleophosmin (NPM1c), CCAAT enhancer binding protein alpha (CEBPA), isocitrate dehydrogenase 1(IDH1; R132, R100 and IDH2; R172, R140) and ten-eleven translocation 2 (TET2) was performed as previously described.
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RESULTS
Baseline Characteristics
Of the 45 patients enrolled, four were excluded (one due to a diagnosis of Chronic Myelomonocytic Leukemia-2 and 3 who died or withdrew consent before receiving a single dose of lenalidomide; 42 patients were therefore evaluable). The median age was 74 (range, 62-86);
27 (66%) were male and 37 (90%) were non-Hispanic white (Table 1) . Secondary AML was noted in 16 patients (7 [17%] had a prior diagnosis of MDS and 9 (22%) had t-AML). Median HCT-CI was 1 (range, 0-7) and 32 (78%) patients had a performance status (PS) of 0 or 1. The median presenting white blood cell count (WBC) was 3,000/µL (range, 500-49,000), platelet count was 51,000/µL (range, 4,000-288,000), and bone marrow blast was 50% (20-91%).
Twelve patients required prior hydroxyurea to maintain the WBC below 10,000/µL (median -6 (3-10) days) and five patients had received prior DNMT inhibitor therapy (aza [4] The median duration of response was 28 weeks (range, 6-104+). Eighteen (44%) patients had resistant disease while 13 of these patients (72%) had a decrease bone marrow blasts. The median OS was 20 weeks (range, 1-121+) for the entire cohort and 69 weeks (range, 10-121+) for responders ( Figure 1A ; responders had better OS compared to non-responders (69 vs. 15
weeks, p-value <0.01) ( Figure 1B ). Although the total number of responders is small, the OS did not differ between patients with a PR versus CR/CRi (p-value = 0.06) (Figure 2A) 
Adverse events and dose modifications
Overall, 196 cycles of the current combination of drugs were administered to 42 patients (mean 4.7 cycles/patient). The most common reason for removal from the study was disease progression (63%), followed by infections complications in the absence of responses (22%). No patients were removed from study due to treatment-related toxicities. Table 2 summarizes the associated AEs. Most adverse events were Grade <2 with vomiting, reaction at the injection site and constipation being the most common toxicities. Grade 3 AEs were relatively uncommon.
After patients experienced responses, infectious complications or fevers were uncommon.
Reductions on the lenalidomide dose due to neutropenia (45%), fatigue (27%) or rash (18%)
were necessary in 11/17 responding patients after a median of 10, 5 and 2.5 cycles, respectively.
Only one patient required an azacitidine dose reduction due to recurrent grade 4 neutropenia after 5 cycles. Deep venous thrombosis with an associated pulmonary embolism was noted in one patient upon platelet count recovery after achievement of first CR.
Molecular and Clinical Predictors of Response
Baseline features associated with clinical responses were lower HCT-CI scores and de novo AML. No correlations between age at diagnosis, baseline WBC count, bone marrow blast percentage or ELN risk classification were noted ( 14, 15, 16 The optimal treatment for these patients requires the consideration of multiple factors, such as patient and disease-related factors that can help to determine the appropriate therapy. Both azacitidine and lenalidomide have single-agent activity in patients older than 60 years with untreated AML and have non-overlapping mechanisms of action that may complement each other. 4, 17 Our results suggest that sequential administration of azacitidine and lenalidomide is an outpatient-based alternative treatment option for untreated elderly AML patients, is associated with a higher overall response rate than seen with either agent alone, and is relatively well tolerated.
This treatment schedule is unique in several ways. First, both agents are given sequentially near the previously established MTD with minimal increase in toxicity and possibly increased efficacy. Preclinical data suggests that sequential administration of lenalidomide augmented the cytotoxic effects of the cytidine analog cytarabine, while concomitant exposure to these agents had antagonistic effects, 6 although this observation was not confirmed in two recent clinical reports. 18 Second, we used a different dose intensity schedule for lenalidomide (50mg PO x 21 days given every 6 weeks) than previously reported. 17, 19 The MTD of lenalidomide was 50mg daily for 21 out of every 28 days and most patients discontinued treatment due to disease progression after 1 cycle. 20 A follow up study using high-dose lenalidomide (50mg daily)
followed by maintenance doses (10mg daily) had less than one-third of patients starting the third cycle of therapy. 18 Single agent lenalidomide had minimal clinical activity and short survival in AML with del(5q). 20 In comparison, our patients received a median of about five cycles of 13 treatment (~30 weeks) with no dose reductions in 35% of the patients.
In AML, genomic abnormalities are likely the fundamental determinants of response to chemotherapy and survival. 10, 21 In fact, the recently proposed ELN risk classification is a robust prognostic method for relapse-free and overall survival. 22 Remarkably, following the combination of azacitidine plus lenalidomide, the ELN risk classification had a minimal impact on outcomes, as patients with adverse risk genomic abnormalities had similar responses as lower-risk patients. These findings suggest that unknown genomic abnormalities mediate treatment sensitivity in these patients, a possibility reinforced by a recent report which proposes that mutations in DNMT3A may be the best predictor of response for patients treated with DNMT inhibitors. 23 In addition, work previously reported by our group suggests that a specific methylation profile may predict benefit from this combination. 
